Stomach cancer laboratory findings

Revision as of 21:26, 6 November 2017 by Medhat (talk | contribs)
Jump to navigation Jump to search

Stomach cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Stomach Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Endoscopy and Biopsy

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Stomach cancer laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Stomach cancer laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Stomach cancer laboratory findings

CDC on Stomach cancer laboratory findings

Stomach cancer laboratory findings in the news

Blogs on Stomach cancer laboratory findings

Directions to Hospitals Treating Stomach cancer

Risk calculators and risk factors for Stomach cancer laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Stomach cancer laboratory findings

0verview

A complete blood cell count (CBC) can identify anemia, which is present in approximately 30% of patients and may be caused by bleeding, liver dysfunction, or poor nutrition

Electrolyte panels and liver function tests also are essential to better characterize the patient's clinical state

Carcinoembryonic antigen (CEA) is increased in 45-50% of cases

Cancer antigen (CA) 19-9 is elevated in about 20% of cases

Distinctive serum glycan patterns may have the potential to serve as markers for gastric cancer risk. In a study of 72 serum samples from patients with gastric cancer, nonatrophic gastritis, or duodenal ulcer, Ozcan and colleagues found that abnormal patterns of serum glycans (sugars attached to proteins) may be useful as a screening tool for identifying patients with Helicobacter pylori infection who are at risk for stomach cancer. [[null 30], [null 31]]

Serum levels of carcinoembryonic antigen (CEA), the glycoprotein CA 125 antigen (CA 125), CA 19-9 (carbohydrate antigen 19-9, also called cancer antigen 19-9), and cancer antigen 72-4 (CA72 4) may be elevated in patients with gastric cancer [68-72].

However, low rates of sensitivity and specificity prevent the use of any of these serologic markers as diagnostic tests for gastric cancer.

In a minority of patients, a drop in an elevated level of CEA and/or CA 125 may correlate with response to preoperative therapy, but clinical decisions are almost never made based upon tumor marker changes alone.

Some gastric cancers are associated with elevated serum levels of alpha-fetoprotein (AFP);

they are referred to as alpha-fetoprotein producing gastric cancers [85-88]. A subset, hepatoid adenocarcinomas of the stomach, has a histologic appearance that is similar to that of hepatocellular cancer (HCC). Regardless of morphology, AFP-producing gastric cancers are aggressive and associated with a poor prognosis.

Increases in serum pepsinogen II or decreases in the pepsinogen I:pepsinogen II ratio has been used in population screening programs to identify patients at increased risk for gastric cancer but are insufficiently sensitive or specific for establishing a diagnosis in an individual patient.

A total of 19 significant differences in serum glycan expression were found between gastric cancer patients and individuals with asymptomatic nonatrophic gastritis. High-mannose–type glycans, glycans with 1 complex type antenna, and bigalactosylated biantennary glycans tended to be lower in gastric cancer patients, whereas levels of nongalactosylated biantennary glycans were higher. Altered serum glycan levels were also seen in study patients with ulcers. [[null 30], [null 31]]

References

Template:WH Template:WS